Cleaved-F7 (R212) Antibody

What is Cleaved-F7 (R212) Antibody and what epitope does it recognize?

The Cleaved-F7 (R212) antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of activated Factor VII light chain (LC) protein fragments resulting from cleavage adjacent to arginine 212 (R212). This antibody was generated using a synthesized peptide derived from human Factor VII (F7) spanning amino acids 171-220, which encompasses the cleavage site . The specificity for the cleaved form makes it particularly valuable for studying coagulation factor activation events rather than simply detecting total Factor VII protein levels. The antibody targets the internal region of Factor VII LC, providing researchers with a tool to monitor the activation status of this crucial coagulation factor .

What applications has the Cleaved-F7 (R212) Antibody been validated for?

The Cleaved-F7 (R212) antibody has been validated for multiple research applications with specific working parameters for each method:

The antibody has demonstrated reactivity with human, rat, and mouse samples, making it versatile for comparative studies across these species . Validation images from the manufacturers confirm specific binding to the target protein in various experimental contexts, including detection in Jurkat cells treated with etoposide (25μM for 24h) and in human breast carcinoma tissue sections .

What are the critical storage and handling parameters for maintaining antibody performance?

To maintain optimal activity, the Cleaved-F7 (R212) antibody should be stored at -20°C for long-term preservation (up to 1 year from the date of receipt) . For frequent use within a short period, storage at 4°C for up to one month is acceptable, but repeated freeze-thaw cycles should be strictly avoided as they significantly degrade antibody performance . The antibody is supplied as a liquid formulation in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide as a preservative . When working with the antibody, it's advisable to aliquot it upon first thaw to minimize freeze-thaw cycles. Researchers should note that the antibody's performance may gradually decrease after multiple experimental uses, even with proper storage conditions, so validation against positive controls should be performed periodically.

How should Western blot protocols be optimized for detecting cleaved Factor VII fragments?

When optimizing Western blot protocols for the Cleaved-F7 (R212) antibody, several critical parameters require careful consideration:

• Sample preparation: Use protein extraction buffers containing protease inhibitors to prevent artificial proteolysis. For cell lysates, RIPA buffer supplemented with a complete protease inhibitor cocktail is recommended to preserve the integrity of cleaved fragments.

• Protein loading: Load 20-40μg of total protein per lane, though this may need adjustment based on expression levels in your specific sample type.

• Gel percentage: Use 10-12% polyacrylamide gels for optimal resolution of Factor VII fragments (the calculated molecular weight of Factor VII is approximately 51.6 kDa) .

• Transfer conditions: Wet transfer at 100V for 60-90 minutes or overnight transfer at 30V is recommended for complete transfer of proteins.

• Blocking: Use 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature to reduce background without affecting antibody binding specificity.

• Antibody incubation: Dilute the antibody in the range of 1:500-1:2000 in blocking buffer and incubate overnight at 4°C for optimal signal-to-noise ratio .

• Detection system: Use enhanced chemiluminescence (ECL) systems with exposure times adjusted empirically based on signal intensity.

Validation studies have demonstrated successful detection of cleaved Factor VII fragments in Jurkat cells treated with etoposide (25μM for 24h), which can serve as a positive control for your experimental setup .

What controls are essential when using Cleaved-F7 (R212) Antibody in experimental systems?

Implementing appropriate controls is crucial for accurate interpretation of results when using the Cleaved-F7 (R212) antibody:

• Positive control: Jurkat cells treated with etoposide (25μM for 24h) have been validated to show cleaved Factor VII fragments and can serve as a reliable positive control .

• Negative control: Untreated cells that express Factor VII but do not undergo significant apoptosis or coagulation cascade activation.

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish specific signal, confirming antibody specificity. This has been demonstrated in both Western blot and immunohistochemistry applications .

• Loading control: Include antibodies against housekeeping proteins (β-actin, GAPDH) to normalize for loading differences between samples.

• Isotype control: Use rabbit IgG at the same concentration as the primary antibody to identify potential non-specific binding.

• Secondary antibody-only control: Omit primary antibody to assess background from the secondary antibody.

• Knockout/knockdown validation: Where possible, samples with genetic deletion or knockdown of Factor VII provide the most stringent control for antibody specificity.

When reporting results, researchers should document all controls used to validate the specificity of the observed signals, particularly when investigating novel experimental conditions or biological systems.

How does sample preparation affect the detection of cleaved Factor VII fragments?

Sample preparation significantly influences the detection of cleaved Factor VII fragments, with several critical considerations:

• Tissue extraction method: For tissue samples, rapid freezing in liquid nitrogen followed by homogenization in cold lysis buffer is essential to prevent artificial proteolysis that could generate misleading cleavage products.

• Protease inhibitor cocktail: Always include a comprehensive protease inhibitor cocktail in lysis buffers to prevent post-lysis proteolysis. For Factor VII studies, inhibitors of serine proteases are particularly important.

• Denaturing conditions: Use of strong denaturing conditions (SDS, heat) is necessary to fully solubilize membrane-associated Factor VII, but may affect epitope recognition if excessive.

• Phosphatase inhibitors: Include these when studying potential interaction between coagulation and signaling pathways, as phosphorylation states may influence cleavage events.

• Sample storage: Minimize storage time of prepared samples, as freeze-thaw cycles can lead to degradation and artificial cleavage products. If storage is necessary, maintain samples at -80°C.

• Reduction conditions: The presence and concentration of reducing agents can affect antibody recognition, as Factor VII contains multiple disulfide bonds that influence protein conformation.

• Cell culture conditions: For in vitro studies, factors like serum concentration, cell density, and stress conditions can all influence Factor VII expression and cleavage patterns.

Researchers have observed that sample preparation artifacts can be distinguished from genuine physiological cleavage events by comparing multiple preparation methods and including appropriate controls in experimental design.

How do post-translational modifications of Factor VII impact Cleaved-F7 (R212) antibody recognition?

Factor VII undergoes numerous post-translational modifications that can significantly impact epitope accessibility and antibody recognition:

• Vitamin K-dependent carboxylation: The enzymatic carboxylation of glutamate residues allows Factor VII to bind calcium, which is essential for its coagulation function. This modification alters protein conformation and can potentially affect antibody binding to nearby epitopes .

• Hydroxylation: The iron and 2-oxoglutarate-dependent 3-hydroxylation of aspartate and asparagine residues in EGF domains is (R) stereospecific and contributes to proper protein folding .

• Glycosylation patterns: Factor VII undergoes both O- and N-glycosylation, with distinct temporal regulation. N-glycosylation at Asn-205 occurs cotranslationally and is mediated by STT3A-containing complexes, while glycosylation at Asn-382 is post-translational and mediated by STT3B-containing complexes . Since Asn-205 falls within the immunogen region (171-220), glycosylation at this site could potentially interfere with antibody recognition.

• O-fucosylation: POFUT1 catalyzes O-fucosylation on conserved serine or threonine residues within the consensus sequence C2-X(4,5)-S/T-C3 of EGF domains, where C2 and C3 are the second and third conserved cysteines . This modification may affect protein conformation and epitope accessibility.

• Proteolytic processing: The primary purpose of the Cleaved-F7 (R212) antibody is to detect Factor VII after proteolytic cleavage at R212, which generates light chain fragments. The antibody's specificity for these cleaved forms depends on the exposure of neo-epitopes created by this cleavage event.

When interpreting experimental results, researchers should consider how sample preparation methods and experimental conditions might alter these modifications and subsequently affect antibody recognition patterns. For instance, deglycosylation treatments may be necessary to achieve consistent detection in some experimental systems.

What methodological approaches can distinguish between uncleaved and cleaved forms of Factor VII?

Distinguishing between uncleaved and cleaved forms of Factor VII requires complementary methodological approaches:

• Parallel antibody analysis: Compare results using antibodies targeting different epitopes - the Cleaved-F7 (R212) antibody (specific for cleaved form) alongside antibodies recognizing total Factor VII (both cleaved and uncleaved forms).

• Size-based separation: The light chain fragment generated by cleavage at R212 has a distinctly lower molecular weight than intact Factor VII. Using high-resolution SDS-PAGE (12-15% gels) can separate these forms based on size differences.

• 2D gel electrophoresis: Combining isoelectric focusing with SDS-PAGE can separate cleaved and uncleaved forms based on both charge and size differences, providing enhanced resolution.

• Immunoprecipitation followed by mass spectrometry: This approach allows precise identification of cleavage sites and can distinguish between various proteolytic fragments.

• Functional assays: Cleaved (activated) Factor VII exhibits enhanced coagulation activity compared to the zymogen form. Parallel assessment of activity can confirm the presence of cleaved, functionally active protein.

• Peptide competition assays: Using synthetic peptides corresponding to regions around the R212 cleavage site can help confirm antibody specificity for the cleaved form versus intact protein .

• Confocal microscopy with colocalizing markers: In cellular systems, activated Factor VII may exhibit distinct subcellular localization patterns compared to the zymogen form, which can be visualized using immunofluorescence techniques.

By employing these complementary approaches, researchers can generate more robust evidence for the presence and relative abundance of cleaved versus uncleaved Factor VII in their experimental systems.

How do experimental conditions affect the generation and detection of cleaved Factor VII in vitro?

Various experimental conditions significantly impact both the generation and detection of cleaved Factor VII in vitro:

• Serum concentration: Serum contains numerous proteases and coagulation factors that can influence Factor VII cleavage. Serum-free conditions may reduce background cleavage but might also alter cellular metabolism and stress responses.

• Cell density and confluence: Overcrowded cultures often experience increased cellular stress and death, potentially triggering coagulation cascade activation and Factor VII cleavage as secondary effects.

• Hypoxia: Low oxygen conditions can alter protease activity and cellular stress responses, potentially affecting Factor VII cleavage patterns. Controlled oxygen conditions are essential for reproducible results.

• Calcium concentration: Factor VII activation is calcium-dependent, and variations in calcium levels between experimental buffers can significantly impact cleavage efficiency.

• pH fluctuations: Protease activity is highly pH-dependent, with optimal activity ranges that vary between enzymes. Maintaining consistent pH throughout sample processing is crucial.

• Temperature: Both enzymatic cleavage reactions and antibody binding kinetics are temperature-dependent. Consistent temperature control throughout sample processing is essential.

• Mechanical stress: Cell harvesting methods (scraping vs. enzymatic detachment) can trigger stress responses that activate proteolysis pathways.

• Apoptosis inducers: Compounds like etoposide (25μM for 24h) have been validated to induce Factor VII cleavage in Jurkat cells and can serve as positive controls, but the mechanism may involve multiple cellular pathways .

Researchers should systematically document and control these variables to ensure reproducible generation and detection of cleaved Factor VII across experiments and between laboratories.

What are the common causes of high background when using Cleaved-F7 (R212) Antibody in immunoassays?

High background is a frequent challenge when working with the Cleaved-F7 (R212) antibody. Several methodological issues and their solutions include:

• Insufficient blocking: Increase blocking concentration (5-10% BSA or non-fat dry milk) and extend blocking time to 2 hours at room temperature.

• Cross-reactivity with endogenous Fc receptors: Pre-incubate samples with non-specific IgG from the same species as your secondary antibody to block Fc receptors.

• Excessive antibody concentration: Titrate the antibody to find the optimal concentration that maximizes specific signal while minimizing background. Start with the recommended dilution range (WB: 1:500-1:2000; IHC: 1:100-1:300; ELISA: 1:20000) and adjust as needed.

• Inadequate washing: Increase wash volume, duration, and number of wash steps. For Western blots, at least 3-4 washes of 10 minutes each with TBST is recommended.

• Sample protein overloading: Excessive protein can lead to non-specific binding. Reduce the amount of protein loaded per lane (15-30μg is typically sufficient).

• Secondary antibody cross-reactivity: Use highly cross-adsorbed secondary antibodies specific to rabbit IgG to minimize non-specific binding.

• Autofluorescence/endogenous peroxidase activity: For IF or IHC, include appropriate quenching steps (H₂O₂ treatment for peroxidase activity; sodium borohydride for autofluorescence).

• Non-specific binding to glycosylated proteins: If glycosylation is suspected to cause cross-reactivity, consider testing deglycosylated samples.

Thorough documentation of optimization steps will help identify the most effective conditions for your specific experimental system and ensure reproducibility.

How can researchers resolve weak or absent signals when using Cleaved-F7 (R212) Antibody?

When faced with weak or absent signals, consider these methodological adjustments:

• Protein extraction efficiency: Ensure complete extraction of target protein by using stronger lysis buffers (RIPA with 0.1% SDS) and thorough homogenization.

• Epitope masking by fixation: For IHC or IF applications, test different fixation methods or include an antigen retrieval step. Heat-induced epitope retrieval in citrate buffer (pH 6.0) has been successful for many Factor VII antibodies.

• Transfer efficiency: For Western blots, verify transfer efficiency by reversible protein staining of membranes (Ponceau S). Consider longer transfer times or lower percentage gels for higher molecular weight proteins.

• Degraded antibody: The antibody may lose activity after multiple freeze-thaw cycles. Use fresh aliquots stored at -20°C or -80°C .

• Low abundance target: Increase protein loading or implement enrichment strategies (immunoprecipitation) prior to Western blotting.

• Incompatible detection system: Switch between chemiluminescence, fluorescence, or colorimetric detection systems to determine optimal sensitivity.

• Insufficient incubation time: Extend primary antibody incubation to overnight at 4°C to enhance binding.

• Stimulation conditions: If detecting activation-dependent cleavage, verify your stimulation protocol. For example, etoposide treatment (25μM for 24h) has been validated to induce Factor VII cleavage in Jurkat cells .

• Membrane type: PVDF membranes typically provide better protein retention than nitrocellulose, which may be beneficial for low-abundance targets.

The Cleaved-F7 (R212) antibody has been successfully used to detect endogenous levels of cleaved Factor VII in various experimental systems, suggesting that optimization rather than lack of compatibility is usually the issue when signals are weak or absent.

How should researchers interpret contradictory results between different applications using Cleaved-F7 (R212) Antibody?

When facing contradictory results across different applications, consider these analytical approaches:

• Application-specific sample preparation effects: Different methods (WB, IHC, ELISA) involve distinct sample processing steps that can affect epitope accessibility. For example, the strong denaturing conditions in Western blotting may expose epitopes that remain masked in the milder conditions of immunohistochemistry.

• Context-dependent protein conformation: The three-dimensional folding of proteins can differ between in vitro and in situ conditions, affecting antibody access to the R212 cleavage site.

• Cross-reactive epitopes: The antibody may recognize similar epitopes in different proteins with varying affinity depending on the experimental conditions. Peptide competition assays can help confirm specificity in each application .

• Fixation artifacts: In IHC or IF, different fixatives (paraformaldehyde, methanol, acetone) can cause distinct conformational changes that affect epitope recognition.

• Application-specific sensitivity thresholds: ELISA typically offers greater sensitivity (recommended dilution 1:20000) compared to Western blotting (1:500-1:2000) or IHC (1:100-1:300) , potentially leading to detection in one method but not another.

• Post-translational modification interference: Modifications like glycosylation at Asn-205 (within the immunogen region 171-220) may have application-specific effects on antibody binding .

• Validation with complementary methods: When contradictions arise, orthogonal approaches (activity assays, mass spectrometry) can help resolve ambiguities and determine which application provides the most reliable results for your specific research question.

When publishing research using this antibody, transparently report any application-specific differences and provide a reasoned interpretation based on controls and validation experiments.

How can Cleaved-F7 (R212) Antibody contribute to cardiovascular disease research?

The Cleaved-F7 (R212) antibody offers valuable insights into cardiovascular pathophysiology through several research applications:

• Thrombosis models: The antibody enables quantification of Factor VII activation in experimental thrombosis, helping elucidate the temporal dynamics of coagulation cascade initiation in various vascular beds.

• Atherosclerotic plaque stability: Factor VII activation within atherosclerotic plaques may contribute to their thrombogenicity. Immunohistochemistry with this antibody allows spatial mapping of activation patterns relative to other plaque features (lipid core, fibrous cap, inflammatory cells).

• Tissue factor pathway analysis: As Factor VII interacts with tissue factor to initiate coagulation, this antibody helps distinguish between the presence of coagulation factors and their functional activation state in cardiovascular tissues.

• Myocardial infarction studies: The antibody can track Factor VII activation in ischemic tissues, potentially identifying temporal windows for anticoagulant intervention.

• Biomarker development: Analysis of cleaved Factor VII in plasma samples may provide prognostic information in cardiovascular disease states, complementing existing biomarkers.

• Therapeutic monitoring: When testing anticoagulant therapies targeting the Factor VII pathway, this antibody offers a direct measure of intervention success at the molecular level.

• Vascular injury responses: The antibody can help characterize the coagulation response to various forms of vascular injury, informing the development of strategies to prevent pathological thrombosis while preserving beneficial hemostasis.

This antibody is particularly valuable in cardiovascular research because it specifically recognizes the activated form of Factor VII, providing insight into functional coagulation states rather than merely detecting factor presence .

What methodological considerations are important when investigating Factor VII activation in cancer research?

When studying Factor VII activation in cancer contexts, researchers should consider these methodological approaches:

• Tumor microenvironment heterogeneity: Single-cell techniques combined with the Cleaved-F7 (R212) antibody can map activation patterns across different tumor regions, correlating with hypoxia markers, inflammatory infiltrates, or necrotic zones.

• Tissue processing speed: Rapid fixation or freezing of tumor samples is critical to prevent artificial activation of coagulation factors ex vivo, which could confound results.

• Co-registration with tissue factor expression: Parallel staining for tissue factor and cleaved Factor VII provides insight into the spatial relationship between the initiator and its activated substrate in the tumor microenvironment.

• Comparative analysis across tumor types: Systematic comparison of Factor VII activation patterns across different malignancies may reveal cancer-specific coagulation signatures with diagnostic or therapeutic implications.

• Cell line validation: Establish baseline activation patterns in relevant cancer cell lines under controlled conditions before proceeding to more complex tumor models or clinical samples.

• Three-dimensional culture systems: Traditional monolayer cultures may not recapitulate the complex coagulation environments of tumors. Organoids or spheroid models may provide more physiologically relevant activation patterns.

• Correlation with clinical parameters: When studying human samples, rigorous documentation of clinical variables (tumor stage, treatment history, thrombotic events) is essential for meaningful correlation with Factor VII activation patterns.

Researchers have successfully applied the Cleaved-F7 (R212) antibody in human breast carcinoma tissue, demonstrating its utility in cancer research contexts . This antibody helps elucidate the increasingly recognized role of coagulation factors in cancer progression beyond their classical hemostatic functions.

How does Factor VII cleavage relate to cellular stress responses and apoptosis pathways?

The relationship between Factor VII cleavage, cellular stress, and apoptosis involves complex interactions with methodological implications:

• Mechanistic overlap: Certain proteases activated during apoptosis can cleave coagulation factors including Factor VII. The Cleaved-F7 (R212) antibody has been validated in etoposide-treated Jurkat cells (25μM for 24h), a model system for studying apoptosis-induced Factor VII cleavage .

• Temporal dynamics: Time-course experiments reveal that Factor VII cleavage may occur at specific stages of the apoptotic cascade, requiring careful experimental timing for detection.

• Subcellular localization shifts: During cellular stress, Factor VII may undergo translocation between compartments, affecting its accessibility to both activating proteases and detection antibodies.

• Membrane externalization: Phosphatidylserine externalization during early apoptosis creates a procoagulant cell surface that can enhance Factor VII activation. This process can be studied by combining the Cleaved-F7 (R212) antibody with markers of membrane reorganization.

• Cross-talk with inflammatory signaling: Stress-induced inflammatory pathways can regulate tissue factor expression, indirectly affecting Factor VII activation. Multiplex analysis combining inflammatory and coagulation markers provides a more complete picture.

• Alternative cleavage sites: Beyond the canonical R212 site, cellular stress may induce Factor VII cleavage at alternative positions, potentially requiring additional antibodies targeting different epitopes for comprehensive analysis.

• Non-coagulation functions: Cleaved Factor VII may have signaling roles distinct from its coagulation function, particularly in cell survival and migration pathways. Combining functional assays with antibody detection helps elucidate these dual roles.

By systematically investigating these relationships, researchers can better understand how coagulation factor activation integrates with cellular stress responses across different physiological and pathological contexts.

What emerging technologies might enhance the utility of Cleaved-F7 (R212) Antibody in coagulation research?

Several cutting-edge technologies promise to expand the research applications of the Cleaved-F7 (R212) antibody:

• Single-cell proteomics: Integration of the antibody into mass cytometry (CyTOF) or single-cell Western blotting platforms would enable analysis of Factor VII activation heterogeneity at the individual cell level within complex tissues.

• Proximity ligation assays (PLA): This technique could reveal in situ interactions between cleaved Factor VII and its binding partners with nanometer resolution, providing spatial context to activation events.

• Intravital microscopy: Fluorescently labeled derivatives of the antibody could enable real-time visualization of Factor VII activation in living tissues, particularly in thrombosis models.

• Biomaterial surface analysis: The antibody could help characterize Factor VII activation on various biomaterial surfaces, informing the development of more hemocompatible medical devices.

• Microfluidic "organ-on-chip" platforms: These systems enable precise control of fluid dynamics and cellular interactions, creating physiologically relevant models for studying Factor VII activation under flow conditions.

• CRISPR-engineered reporter systems: Cell lines with endogenous Factor VII modified to include fluorescent tags near the R212 cleavage site could provide complementary approaches to antibody-based detection.

• Machine learning image analysis: Advanced computational approaches could extract subtle patterns of Factor VII activation from immunohistochemistry data that might not be apparent through conventional analysis.

These technological advances, combined with the specificity of the Cleaved-F7 (R212) antibody for the activated form of Factor VII, will enhance our understanding of coagulation biology in both physiological and pathological contexts.

How might differential glycosylation patterns affect Factor VII cleavage detection across experimental systems?

Glycosylation variability introduces significant complexity to Factor VII cleavage detection, with important methodological implications:

• Species-specific glycosylation patterns: Although the Cleaved-F7 (R212) antibody shows cross-reactivity with human, rat, and mouse samples , glycosylation differences between species may affect epitope accessibility and recognition strength.

• Cell type-specific glycosylation: Factor VII produced in different cell types (hepatocytes vs. cancer cells) may exhibit distinct glycosylation patterns, potentially affecting antibody recognition even within the same species.

• Sample preparation considerations: Deglycosylation treatments (PNGase F, O-glycosidase) can be incorporated into protocols to determine whether glycosylation at Asn-205 (within the immunogen region 171-220) affects antibody binding .

• In vitro expression systems: Recombinant Factor VII produced in different expression systems (mammalian cells, insect cells, yeast) will exhibit system-specific glycosylation that may not match endogenous patterns, affecting comparative studies.

• Disease-associated glycosylation changes: Pathological conditions can alter glycosylation machinery, potentially changing Factor VII glycosylation patterns in disease models. This may necessitate different optimization strategies for detecting cleaved Factor VII in healthy versus pathological samples.

• Analytical approaches: Combining the Cleaved-F7 (R212) antibody with glycan-specific lectins or glycoproteomic analysis can provide insight into how glycosylation status correlates with Factor VII cleavage patterns.

• Temporal regulation of glycosylation: As noted in the search results, N-glycosylation at Asn-205 occurs cotranslationally (mediated by STT3A-containing complexes), while glycosylation at Asn-382 is post-translational (mediated by STT3B-containing complexes) . This temporal separation may have functional significance for Factor VII activation.